Drug Profile
Eftilagimod alpha - Immutep Limited
Alternative Names: EDP 202; Efti; EOC-202; hLAG-3Ig; ImmuFact IMP321; ImmuFact-IMP321; IMP 321; LAG-3-Ig-fusion-protein; LAG-3Ig; sLAG-3-IgLatest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Immutep
- Developer CYTLIMIC; EOC Pharma; Immutep; Immutep Limited; Krankenhaus Nordwest; Merck & Co; Prima BioMed
- Class Adjuvants; Antineoplastics; CD antigens; Immunoglobulins; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Histocompatibility antigen class II stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Breast cancer
- Phase II COVID 2019 infections; Non-small cell lung cancer; Soft tissue sarcoma; Squamous cell cancer
- Phase I Liver cancer; Malignant melanoma; Solid tumours
- No development reported Renal cell carcinoma
- Discontinued Hepatitis B
Most Recent Events
- 05 Mar 2024 Efficacy and adverse events data from the phase II/III AIPAC-003 trial in Breast cancer released by Immutep Limited
- 21 Dec 2023 Paul-Ehrlich-Institut (PEI) provides positive feedback for eftilagimod alpha for TACTI 004 phase-III trial for Non-small cell lung cancer (First-line therapy, Metastatic disease)
- 09 Nov 2023 Immutep and Merck Sharp & Dohme completes enrollment in the phase II TACTI-003 trial for Squamous cell carcinoma of head and neck (First line therapy, Metastatic disease, Combination therapy, Inoperable/Unresectable) in the US, Australia, Belgium, Denmark, Germany, Spain, Romania, Ukraine, and the UK (SC) (NCT04811027)